Home PROCEPT BioRobotics Corporation

PROCEPT BioRobotics Corporation

New Clinical and Real-World Data Highlighting Effectiveness, Durability, Superior Safety and Reproducibility of Aquablation® Therapy for BPH

The company reports new clinical data confirms that PROCEPT BioRobotics’ Aquablation therapy is a durable, safe, effective and reproducible minimally invasive surgical treatment option for benign prostatic hyperplasia

Data From WATER, WATER II and Single-Center Studies of PROCEPT BioRobotics Aquablation Therapy Will Be Revealed at the AUA

Two pivotal studies and one all-comers commercial series featuring PROCEPT® BioRobotics  Aquablation® therapy for the treatment of benign prostatic hyperplasia (BPH) will be presented at the American Urological Association (AUA) Annual Meeting at McCormick Place in Chicago, May 3 - 6, 2019. Aquablation therapy, delivered by the AquaBeam® Robotic System, is the only FDA cleared, autonomous robot for surgery.

Six-Month Data Highlight Safety and Efficacy of PROCEPT BioRobotics’ Aquablation® Therapy as an Effective Minimally Invasive Surgical Treatment for BPH in Prostates up to...

3/12/19: Six-month data from the Francais WATER Study (Waterjet Ablation Therapy for Endoscopic Resection of prostate tissue) evaluating the safety and efficacy of Aquablation therapy at three centers in France will be presented in an expert guided poster tour by Vincent Misrai, M.D., a urologic surgeon at Clinique Pasteur in Toulouse, France.

NIH and Clinical Excellence in the UK issued an Interventional Procedure Guidance Recommendation Approving Use of Aquablation® Therapy as an Alternative to Other Surgical...

10/1/18:“The NICE guidance is the first step in gaining full endorsement for widespread use of Aquablation in the UK,” said Nikolai Aljuri, PhD, PROCEPT BioRobotics co-founder, CEO and president.

PROCEPT BioRobotics’ Aquablation Meets Primary Endpoints in WATER II Study of 80 to 150 Milliliter Prostates

5/21/18: “On the heels of the WATER Study, the results of the WATER II Study confirmed Aquablation delivers predictable and reproducible results regardless of the size of the prostate,” said Dr. Desai.

PROCEPT BioRobotics Announces Milestones in Europe

PROCEPT BioRobotics, a Silicon Valley surgical robotics company developing novel and disruptive technologies to treat prostate disease, announced that the first commercial Aquablation® procedures have been completed in Germany. Additionally, the company has initiated the FRANCAIS WATER clinical trial, a necessary first step in gaining reimbursement for the company’s AquaBeam® System in France.

PROCEPT BioRobotics Announces First Patients Treated in WATER II Pivotal Clinical Trial

PROCEPT BioRobotics describes The WATER II study as a U.S. investigational device exemption (IDE) clinical trial evaluating the safety and efficacy of Aquablation, delivered...

Procept BioRobotics’ Aquablation Shows Superior Results vs. TURP in WATER Blinded Randomized Trial for BPH

Aquablation, delivered by Procept BioRobotics' AquaBeam® System, uses a robotically controlled waterjet to remove prostate tissue without the application of heat. The double blind,...

Must Read

New Research Demonstrates Advantages of ExactechGPS® for Knee and Shoulder Joint Replacement

ExactechGPS is a dynamic computer-assisted technology that enhances the surgical experience with active intraoperative feedback for real-time execution in a compact and mobile system within the sterile field.

Merry X-Ray Corporation Announces Significant Shift in Their Sales and Marketing Strategies

The company will be consolidating all of their existing companies and acquisitions past and present under one strong umbrella identity: MXR The Imaging Solution Company.